Clinical Trial Update: Tadalafil for Sarcoidosis Associated Pulmonary Hypertension [Phase 2, Phase 3]

View source ↗

Summary

This document reports results from a Phase 2/3 trial evaluating tadalafil for sarcoidosis-associated pulmonary hypertension, with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sarcoidosis-associated Pulmonary Hypertension

Drugs mentioned

• TADALAFIL (TADALAFIL)

Snippet

Sponsor: University of North Carolina, Chapel Hill | Conditions: Pulmonary Hypertension | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2017-07-24